Dr. Jialin Luo 罗加林
Chief Physician
Department of Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy and comprehensive care for rectal, gastric, pancreatic, liver, bile duct, prostate, bladder cancers, lymphoma, and soft tissue sarcoma. Specializes in heavy ion radiotherapy.
Dr. Luo holds a PhD in Oncology and serves as a Master’s supervisor. With extensive experience in radiation therapy for abdominal tumors and lymphoma, particularly heavy ion radiotherapy, Dr. Luo has published over 20 papers and led or participated in multiple research projects.
Professional roles
- Member, Gastric Cancer Group, Radiotherapy Professional Committee, China Anti-Cancer Association
- Member, Lymphoma Group, Radiotherapy Professional Committee, Chinese Medical Doctor Association
- Deputy Leader, Pelvic Floor Rehabilitation Group, Physical Medicine and Rehabilitation Committee, Zhejiang Medical Association
- Member, Colorectal Cancer Professional Committee, Zhejiang Alliance of China Tumor Prevention and Treatment Union
Name order: in Chinese the family name comes first (Luo Jialin). Papers usually list the name as Jialin Luo or Luo J.
Selected publications
16 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Med Rep, 2021 (first author): miR‑576‑5p promotes epithelial‑to‑mesenchymal transition in colorectal cancer by targeting the Wnt5a‑mediated Wnt/β‑catenin signaling pathway. PubMed 33300054
- J Clin Lab Anal, 2020 (senior author): Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. PubMed 32608537
- Pathol Res Pract, 2019 (senior author): Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib. PubMed 31387809
- Gene, 2018 (first author): miR-519b-3p promotes responsiveness to preoperative chemoradiotherapy in rectal cancer patients by targeting ARID4B. PubMed 29477868
- Onco Targets Ther, 2016 (first author): Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma. PubMed 27785062
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion